Lawsuit claims Pfizer fellowship program is biased against whites, Asian-Americans
Reuters
Published Sep 15, 2022 06:43PM ET
Updated Sep 15, 2022 07:02PM ET
By Jonathan Stempel
NEW YORK (Reuters) - A group of medical professionals that advocates against "radical, divisive, and discriminatory ideology" in healthcare sued Pfizer Inc (NYSE:PFE) on Thursday, saying the drugmaker runs a fellowship that illegally excludes white and Asian-American applicants.
In a complaint filed in Manhattan federal court, the plaintiff Do No Harm called Pfizer's Breakthrough Fellowship Program "discriminatory on its face" because only Blacks, Latinos and Native Americans can apply.
It said the program violates federal, New York state and New York City civil rights laws, as well as a federal ban on racial discrimination by companies that accept reimbursements from government healthcare programs.
"Racial discrimination demeans us," and Pfizer's "open exclusion of white and Asian-American applicants is illegal," the complaint said, citing opinions of two conservative Supreme Court justices, Clarence Thomas and the late Antonin Scalia.
The lawsuit seeks injunctions barring Pfizer from making race a factor in obtaining fellowships, and preventing it from filling the 2023 class under current eligibility rules. It also seeks $1 in nominal damages.
In a statement, Pfizer said it had not reviewed the lawsuit, but had "every confidence" that the fellowship program complied with all U.S. employment laws.
"We will continue to strive to create more opportunity, including through specific programs designed to cast a wide net for talent," it added.
Do No Harm had no immediate additional comment. The Glen Allen, Virginia-based group said its members include doctors, other healthcare professionals, medical students, patients and policymakers.
Based in New York, Pfizer said the fellowship program https://www.pfizer.com/about/careers/breakthrough-fellowship-program is part of a nine-year commitment to boost minority representation, and that the company aims to enroll 100 fellows by 2025.
Fellows receive two years of full-time jobs after graduating from college, fully-funded master's degrees, and employment at Pfizer after completing the program.
In a statement on Pfizer's website, Chief Executive Albert Bourla said the program can help "lead to parity at all levels to create a vibrant culture where every colleague has the opportunity to succeed."
Get The News You Want
The case is Do No Harm v Pfizer Inc, U.S. District Court, Southern District of New York, No. 22-07908.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.